ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Outcome measures"

  • Abstract Number: 2480 • 2018 ACR/ARHP Annual Meeting

    Patient-Reported Outcome Measures Used in Rheumatoid Arthritis Cohorts and Registries Around the World: An Environmental Scan from the Outcome Measures in Rheumatology Critical Outcomes in Longitudinal Observational Studies Working Group

    Richard Zogala1, Karla Criner2, Maria A. Lopez-Olivo1, Natalia Zamora3, Devesh Rai1, Gregory Pratt4, Jude K. A. des Bordes1, Robin Christensen5 and Maria Suarez-Almazor1, 1Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2Internal Medicine, Baylor College of Medicine, Houston, TX, 3Reumatologia, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, Buenos Aires, Argentina, 4Research Medical Library, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Houston, TX, 5Department of Rheumatology, Musculoskeletal Statistics Unit: The Parker Institute, Bispebjerg and Frederiksberg Hospital, & Department of Rheumatology, Odense University Hospital, Copenhagen, Denmark

    Background/Purpose: International registries and cohorts could potentially provide long-term data on patient-centered outcomes. In recent years there has been a concerted effort to define a…
  • Abstract Number: 341 • 2018 ACR/ARHP Annual Meeting

    Setting Treatment Target for Joint Surgery in Lower Limbs in Patients with Long-Standing Rheumatoid Arthritis Based on Multicenter Prospective Cohort Study; Validation and Reliability of Objective Index of Activity Speed (Timed Up and Go test) for Measuring Physical Function

    Toshihisa Kojima1, Hajime Ishikawa2, Masayo Kojima3, Sakae Tanaka4, Nobuhiko Haga5, Keiichiro Nishida6, Masao Yukioka7, Jun Hashimoto8, Hisaaki Miyahara9, Yasuo Niki10, Tomoatsu Kimura11, Hiromi Oda12, Shuji Asai1, Koji Funahashi13 and Naoki Ishiguro1, 1Orthopaedic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan, 2Orthopedic Surgery, Niigata Rheumatic Center, Shibata, Japan, 3Medical education, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan, 4Department of Orthopaedic Surgery, Faculty of Medicine, The University of Tokyo, Bunkyo-ku, Japan, 5Rehabilitation Medicine, The University of Tokyo Hospital, Tokyo, Japan, 6Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama city, Japan, 7Orthopedic Surgery, Yukioka Hospital, Osaka, Japan, 8Rheumatology/Orthopaedics, Osaka-Minami Medical Ctr, Kawachinagano, Japan, 9Department of Rheumatology and Orthopaedic Surgery, Kyushu Medical Center, Fukuoka, Japan, 10Orthopaedic Surgery, Keio University, School of Medicine, Tokyo, Japan, 11Department of Orthopaedic Surgery, Faculty of Medicine, University of Toyama, Toyama, Japan, 12Department of Orthopaedic Surgery, Saitama Medical University, Saitama, Japan, 13Orthopedic Surgery, Kariya-Toyota General Hospital, Kariya, Japan

    Background/Purpose: Total management including reconstructive joint surgery and rehabilitation should be needed for further improvements of physical function for long-standing RA patients. It is very…
  • Abstract Number: 2562 • 2018 ACR/ARHP Annual Meeting

    Secukinumab Improves Grappa-Omeract Core Domains of Psoriatic Arthritis

    Ana-Maria Orbai1, Iain B. McInnes2, Laura C. Coates3, M. Elaine Husni4, Dafna D Gladman5, Laure Gossec6, Luminita Pricop7, Olivier Chambenoit8, Xiangyi Meng8 and Philip J. Mease9, 1Johns Hopkins University School of Medicine, Baltimore, MD, 2University of Glasgow, Glasgow, United Kingdom, 3Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, 4Cleveland Clinic, Cleveland, OH, 5Toronto Western Research Institute and University of Toronto, Toronto, ON, Canada, 6Université Pierre et Marie Curie and Hôpital Pitié-Salpêtrière, Paris, France, 7Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, East Hanover, NJ, 8Novartis Pharmaceuticals Corporation, East Hanover, NJ, 9Swedish Medical Center and University of Washington, Seattle, WA

    Background/Purpose: Secukinumab, a fully human monoclonal antibody that selectively neutralizes IL-17A, has demonstrated efficacy for patients with psoriatic arthritis (PsA) in multiple phase 3 clinical…
  • Abstract Number: 481 • 2018 ACR/ARHP Annual Meeting

    Stepping It up: The Use of Physical Activity Monitors As an Outcome Measure in Juvenile Myositis

    Emily Brunner1, Laura Tasan2, Kathryn S. Torok3, Bonny Rockette-Wagner4, Christina K. Zigler5, Kaila Schollaert-Fitch3, Diane Koontz6, Chester V. Oddis7 and Rohit Aggarwal8, 1Pediatric Rheumatology, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA, 2Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA, 3Pediatric Rheumatology, University of Pittsburgh Med Ctr, Pittsburgh, PA, 4University of Pittsburgh Medical Center, Pittsburgh, PA, 5Physical Medicine & Rehabilitation, University of Pittsburgh, Pittsburgh, PA, 6Internal Medicine Division of Rheumatology, University of Pittsburgh, Pittsburgh, PA, 7Division of Rheumatology and Clinical Immunology, Department of Medicine, Unviersity of Pittsburgh/University of Pittsburgh Medical Center, Pittsburgh, PA, 8Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh/University of Pittsburgh Medical Center, Pittsburgh, PA

    Background/Purpose: The use of physical activity monitors (PAM), which objectively quantify free-living movement, may enhance assessment of disease activity in juvenile myositis (JM) clinical trials…
  • Abstract Number: 2687 • 2018 ACR/ARHP Annual Meeting

    Patient-Level Evaluation of Components of the American College of Rheumatology Combined Response Index in Systemic Sclerosis (CRISS) Using Patient-Reported Anchors

    Vivek Nagaraja1, John Powers2, Celia J. F. Lin3, Benjamin Brennan4, Veronica J. Berrocal5 and Dinesh Khanna1, 1Division of Rheumatology, Department of Internal Medicine, University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, MI, 2University of Maryland School of Medicine, Rockville, MD, 3Genentech, Inc., South San Francisco, CA, 4School of Public Health, University of Michigan, Ann Arbor, MI, 5Div of Rheumatology, University of Michigan, Ann Arbor, MI

    Background/Purpose: Treatment benefit is demonstrated by evidence that interventions have positive impacts on how patients feel, function, and/or survive (FDA Guidance, 21CFR314.510). The ACR CRISS,…
  • Abstract Number: 681 • 2018 ACR/ARHP Annual Meeting

    Identification of Treatment Naïve Patients with Psoriatic Arthritis Who Will Require a TNF Inhibitor

    Dan Gromer1, Laura C. Coates2, Oliver FitzGerald3, Blanca Himes4, Philip Helliwell5 and Alexis Ogdie6, 1University of Pennsylvania, Medical Student, Philadelphia, PA, 2University of Oxford, Oxford, United Kingdom, 3Department of Rheumatology, St Vincent's University Hospital and Conway Institute, University College Dublin, Ireland, Dublin, Ireland, 4Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, PA, 5LIMM, Section of Musculoskeletal Disease, University of Leeds, Leeds, United Kingdom, 6Medicine/Rheumatology and Epidemiology, University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Psoriatic arthritis (PsA) is a heterogeneous chronic inflammatory disease that affects the skin, joints, and soft tissues. No metrics exist to indicate whether an…
  • Abstract Number: 2783 • 2018 ACR/ARHP Annual Meeting

    EULAR Task Force Recommendations for a Minimum Core Set of Parameters to be Collected in Giant Cell Arteritis Registries and Databases

    Lisa Ehlers1, Johan Askling2, Johannes W. J. Bijlsma3, Maria C. Cid4, Maurizio Cutolo5, Bhaskar Dasgupta6, Christian Dejaco7,8, William G Dixon9, Nils Feltelius10,11, Axel Finckh12, Kate Gilbert13, Sarah Mackie14, Alfred Mahr15, Eric L. Matteson16, Lorna Neill17, Carlo Salvarani18,19, Wolfgang A. Schmidt20, Anja Strangfeld21, Ronald van Vollenhoven22 and Frank Buttgereit1, 1Department of Rheumatology and Clinical Immunology, Charité University Hospital Berlin, Berlin, Germany, 2Unit of Clinical Epidemiology, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden, 3Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, 4University of Barcelona, Barcelona, Spain, 5Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, San Martino Polyclinic Hospital, Genoa, Italy, Genoa, Italy, 6Southend University Hospital NHS Foundation Trust, Westcliff-on-Sea, United Kingdom, 7Department of Rheumatology and Immunology, Medical University Graz, Graz, Austria, Graz, Austria, 8Rheumatology, Hospital of Bruneck, Bruneck, Italy, 9Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, 10Medical Products Agency, Uppsala, Sweden, 11Cross-Committee Task Force on Registries at the European Medicines Agency, London, United Kingdom, 12University Hospital of Geneva, Geneva, Switzerland, 13Patient Representative from PMRGCAuk, London, United Kingdom, 14NIHR-Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, University of Leeds, Leeds, United Kingdom, 15Internal Medicine, Saint-Louis Hospital, Paris Diderot University, Paris, France, 16Division of Rheumatology, Mayo Clinic College of Medicine and Science, Rochester, MN, 17Patient Representative from PMR-GCA Scotland, Perth, United Kingdom, 18Università di Modena e Reggio Emilia, Modena, Italy, 19Azienda USL-IRCCS di Reggio Emilia and Università di Modena e Reggio Emilia, Reggio Emilia, Italy, 20Medical Center for Rheumatology and Clinical Immunology Berlin-Buch, Immanuel Krankenhaus Berlin, Berlin, Germany, 21Epidemiology, German Rheumatism Research Center, Berlin, Germany, 22Amsterdam Rheumatology and Immunology Center ARC, Amsterdam, Netherlands

    Background/Purpose: Giant cell arteritis (GCA) represents the most common form of primary systemic vasculitis, and is frequently associated with comorbidities related either to the disease…
  • Abstract Number: 723 • 2018 ACR/ARHP Annual Meeting

    Patient-Reported Cognitive Screen Does Not Identify Cognitive Sub-Domains: Exploration of the Subscale Structure of the Perceived Deficits Questionnaire in a Systemic Lupus Erythematosus Cohort

    Lisa Engel1, Jiandong Su1, Emily Nalder2, Yael Goverover3, Monique Gignac4, Carmela Tartaglia5, Nicole Anderson1 and Zahi Touma1, 1University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 2Department of Occupational Science and Occupational Therapy, University of Toronto, Toronto, ON, Canada, 3Department of Occupational Therapy, New York University, New York, NY, 4Instititue for Work and Health, Toronto, ON, Canada, 5University of Toronto, Krembil Neurosciences Centre, Toronto, ON, Canada

    Background/Purpose: Identifying patients with Systemic Lupus Erythematosus related cognitive impairment (SLE-CI) is critical as SLE-CI can negatively affect employment, quality of life, and disease self-management.…
  • Abstract Number: 2857 • 2018 ACR/ARHP Annual Meeting

    An Electronic Audit, Reporting, and Data Correction System Improves the Quantity and Quality of Observational Data Collected for US Veterans Enrolled in the Veterans Affairs Rheumatoid Arthritis Registry

    Grant W. Cannon1,2, Jorge Rogas2, Neill Bell3, Joshua Baker4, Gail S. Kerr5, Angelo Gaffo6, J. Steuart Richards7, Jennifer Barton8, Pascale Schwab8, Ted R. Mikuls9, Namrata Singh10, Liron Caplan11, Deana Lazaro12, Andreas Reimold13 and Brian Sauer2, 1Division of Rheumatology, Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, 2Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, 3Salt Lake City VA Medical Center and University of Utah, Dallas VA Medical Center, Dallas, TX, 4Philadelphia VA Medical Center and University of Pennsylvania, Philadelphia, PA, 5Washington VA Medical Center, Georgetown and Howard Universities, Washington, DC, 6Birmingham VA and University of Alabama at Birmingham, Birmingham, AL, 7Pittsburgh VA Medical Center and University of Pittsburgh, Pittsburgh, PA, 8VA Portland Health Care System and Oregon Health and Science, Portland, OR, 9VA Nebraska-Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE, 10Internal Medicine, Iowa City VA Medical Center and University of Iowa, Iowa City, IA, 11Div of Rheumatology, Denver VA Medical Center and University of Colorado, Aurora, CO, 12Brooklyn VA Medical Center and SUNY Downstate, Brooklyn, NY, 13Rheumatology, Dallas VA Medical Center and University of Texas - Southwestern, Dallas, TX

    Background/Purpose:   The Veterans Affairs (VA) Rheumatoid Arthritis (RA) (VARA) registry is an observational cohort study of US Veterans with RA at 11 VA Medical…
  • Abstract Number: 1261 • 2018 ACR/ARHP Annual Meeting

    Development a Core Domain Set to Assess Shared Decision Making Interventions in Rheumatology: An OMERACT White Paper to Facilitate Endorsement

    Karine Toupin-April1, Jennifer Barton2,3, Liana Fraenkel4, Alexa Meara5, Linda Li6, Peter Brooks7, Maarten de Wit8, Dawn Stacey9,10, France Légaré11, Beverly Shea9,12,13, Anne Lyddiatt14, Catherine Hofstetter15, Robin Christensen16, Marieke Scholte-Voshaar17,18, Maria Suarez-Almazor19, Annelies Boonen20, Tanya Meade21,22, Lyn March22, Janet Elizabeth Jull9, Willemina Campbell23, Rieke Alten24, Suvi Karuranga25, Esi Morgan26, Jessica Kaufmann27, Sophie Hill27, Lara J. Maxwell9,10, Dorcas Beaton28, Yasser El-Miedany29, Shikha Mittoo30, Susan J. Bartlett31, Jasvinder A. Singh32 and Peter Tugwell33, 1Children’s Hospital of Eastern Ontario Research Institute, Ottawa, ON, Canada, 2VA Portland Health Care System, Portland, OR, 3Oregon Health & Science University, Portland, OR, 4Yale University School of Medicine, New Haven, CT, 5Internal Medicine/Rheumatology, The Ohio State University Wexner Medical Center, Columbus, OH, 6Arthritis Research Canada, Richmond, BC, Canada, 7The University of Melbourne, Victoria, Australia, 8EULAR standing committee of PARE, Zurich, Switzerland, 9University of Ottawa, Ottawa, ON, Canada, 10The Ottawa Hospital Research Institute, Ottawa, ON, Canada, 11Université Laval, Montreal, QC, Canada, 12Bruyere Research Institute, Ottawa, ON, Canada, 13School of Epidemiology, Public Health, and Preventive Medicine, Faculty of Medicine, University of Ottawa, and Ottawa Hospital Research Institute, Clinical Epidemiology Program, Ottawa, ON, Canada, 14Musculoskeletal Group, Cochrane Collaboration, Hamilton, ON, Canada, 15OMERACT patient research partner group, Ottawa, ON, Canada, 16Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark, 17University of Twente, Enschede, ON, Netherlands, 18OMERACT patient research partner group, Enschede, Netherlands, 19Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 20Department of Rheumatology, Maastricht University Medical Center, Maastricht, The Netherlands, Maastricht, Netherlands, 21Western Sydney University, New South Wales, Australia, 22University of Sydney, New South Wales, Australia, 23OMERACT patient research partner group, Toronto, ON, Canada, 24University Medicine Berlin, Berlin, Germany, 25Access to Medicine Foundation, Haarlem, Netherlands, 26University of Cincinnati, Cincinnati, OH, 27La Trobe University, Victoria, Australia, 28Mobility Program Clinical Research Unit, St Michael's Hospital, Toronto, ON, Canada, 29Ain Shams University, Cairo, Egypt, 30Involved medicine, Toronto, ON, Canada, 31Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, 32Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 33Center For Global Health, Institute of Population Hlth, Ottawa, ON, Canada

    Background/Purpose: Shared decision making (SDM) improves decisional outcomes and patient-physician communication and holds great potential for improving the management of various rheumatology conditions. However, the…
  • Abstract Number: 2871 • 2018 ACR/ARHP Annual Meeting

    Comprehensive Provider Judgement Is a Significant Determinant of Major Therapeutic Change in Patients with Moderate to Severe Rheumatoid Arthritis

    Jacob R. Stever1, Brian C. Sauer1 and Grant W. Cannon2, 1Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, 2Division of Rheumatology, Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT

    Background/Purpose:   We have previously reported an evaluation of 941 US Veterans in the Veterans Affairs (VA) Rheumatoid Arthritis (RA) (VARA) registry that 559 (59%)…
  • Abstract Number: 1446 • 2018 ACR/ARHP Annual Meeting

    The Optimal Joint Set for Ultrasound Assessment of Synovitis in RA: Results from the Rasch Measurement Model

    Elizabeth M.A. Hensor1,2, Alan Tennant3, Philip G. Conaghan1,2, Hilde B Hammer4, Richard J. Wakefield1,2 and Maria Antonietta D'Agostino1,5, 1Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, 2NIHR Leeds Biomedical Research Centre, Chapel Allerton Hospital, Leeds, United Kingdom, 3Swiss Paraplegic Research, Nottwil, Switzerland, 4Rheumatology, Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 5Rheumatology, Versailles-Saint Quentin en Yvelines University- APHP, Ambroise-Paré Hospital, Boulogne-Billancourt, France

    Background/Purpose: The recently introduced composite OMERACT-EULAR power Doppler (PD)/grey scale (GS) ultrasound (PDUS) scoring system for RA with a proposed 18 joint set was developed…
  • Abstract Number: 2906 • 2018 ACR/ARHP Annual Meeting

    Synovitis Focused Ultrasound in Rheumatoid Arthritis: A Joint Reduction Strategy

    Daniel Kuo1, Gurjit Kaeley2, Ami Ben-Artzi3, Jenny Brook4, Astrid Floegel-Shetty4, David Elashoff4 and Veena K. Ranganath1, 1Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, 2Rheumatology, University of Florida College of Medicine, Jacksonville, Jacksonville, FL, 3Rheumatology, Cedars Sinai Medical Center, Beverly Hills, CA, 4Department of Medicine Statistics Core, UCLA David Geffen School of Medicine, Los Angeles, CA

    Background/Purpose: Musculoskeletal ultrasound is increasingly being used as a tool to assess inflammatory burden in rheumatoid arthritis (RA). Ultrasound-based outcome measures include power Doppler (PD)…
  • Abstract Number: 1455 • 2018 ACR/ARHP Annual Meeting

    Development of a Predictive Model of Radiological Damage in Patients with Rheumatoid Arthritis Based on Artificial Intelligence

    Jose M Lezcano1, José Ivorra-Cortes2, Alfredo Madrid3, Raquel Lopez-Mejías4, Javier Martin5, Benjamín Fernández-Gutiérrez6, Miguel Angel González-Gay7, Alejandro Balsa8, Isidoro Gonzalez-Alvaro9, Fernando Salazar10, Lydia A Alcazar11 and Luis Rodriguez-Rodriguez11, 1Helix BioS CEO, Madrid, Spain, 2Rheumatology, University Hospital la Fe, Valencia, Spain, 3Rheumatology Department, and Instituto de Investigación Sanitaria (IdISSC), Hospital Clínico San Carlos, Madrid, Spain, 4Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL, Santander, Spain, Santander, Spain, 5Instituto de Parasitología y Biomedicina López Neyra, Granada, Spain, 6Department of Rheumatology, Hospital Clinico San Carlos, Madrid, Spain, 7School of Medicine, University of Cantabria, Santander, Spain, Santander, Spain, 8Rheumatology Department, Hospital Universitario La Paz, IdiPAZ, Madrid, Spain, 9Rheumatology Department, Hospital Universitario de La Princesa, IIS-IP, Madrid, Spain, 10International Centre for Numerical Methods in Engineering (CIMNE), Madrid, Spain, 11Rheumatology Department and Heath Research Institute (IdISSC), Hospital Clinico San Carlos, Madrid, Spain

    Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory disease associated with increased mortality and disability. Although different factors have been associated with prognosis, it is…
  • Abstract Number: 2911 • 2018 ACR/ARHP Annual Meeting

    Patient-Reported Outcomes Measurement Information System (PROMIS®) Global Health Short Form Is Responsive to Patient Reported Changes in SLE Health Status

    Shanthini Kasturi1, Jackie Szymonifka2, Jessica R. Berman3, Kyriakos A. Kirou3, Alana B. Levine3, Lisa R Sammaritano4 and Lisa A. Mandl4, 1Medicine/Rheumatology, Tufts Medical Center, Boston, MA, 2Hospital for Special Surgery, New York, NY, 3Rheumatology, Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, 4Hospital for Special Surgery/Weill Cornell Medicine, New York, NY

    Background/Purpose: The accurate and efficient serial measurement of patient centered outcomes is a priority in the clinical care of SLE. Patient-Reported Outcomes Measurement Information Systems…
  • « Previous Page
  • 1
  • …
  • 37
  • 38
  • 39
  • 40
  • 41
  • …
  • 49
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology